Vicarious Surgical (RBOT) to Post Earnings on Thursday

Vicarious Surgical (NYSE:RBOT) is anticipated to issue its Q2 2026 resultson Thursday, July 30th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Vicarious Surgical Trading Down 17.5%

Shares of RBOT stock opened at $0.14 on Thursday. The company’s fifty day moving average price is $0.44 and its 200-day moving average price is $1.08. The stock has a market cap of $997,360.00, a PE ratio of -0.02 and a beta of 1.88. Vicarious Surgical has a 12 month low of $0.12 and a 12 month high of $13.75.

Institutional Investors Weigh In On Vicarious Surgical

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its holdings in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock worth $110,000 after purchasing an additional 3,615 shares during the period. Connective Capital Management LLC purchased a new position in shares of Vicarious Surgical during the 3rd quarter valued at about $169,000. Geode Capital Management LLC grew its stake in shares of Vicarious Surgical by 26.0% during the 4th quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock valued at $88,000 after acquiring an additional 8,344 shares during the period. Jane Street Group LLC bought a new position in shares of Vicarious Surgical during the 4th quarter valued at approximately $98,000. Finally, Armistice Capital LLC purchased a new stake in Vicarious Surgical in the 4th quarter worth approximately $1,314,000. Institutional investors own 47.27% of the company’s stock.

About Vicarious Surgical

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.